NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/21/2023
Back to search
Official data from USPTO
HAEVENCI
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
16
Latest update
03/21/2023
Classification
Registered
Trademark type
Word
Nice classes
5
Filing date
11/30/2021
Registration date
03/21/2023
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/21/2023
Last transaction
03/21/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
4
Owner type
16
Owner location
Marburg, DE
Examiner
STIGLITZ, SUSAN
Law office
L90
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
CSL Behring GmbH
Representatives
Scott D. Woldow SMITH, GAMBRELL & RUSSELL, LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE
Publications
History of USPTO decisions and trademark events.
16 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
03/21/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/03/2023
PUBO
PUBLISHED FOR OPPOSITION
01/03/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/14/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/01/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/04/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/04/2022
ALIE
ASSIGNED TO LIE
11/04/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/21/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/08/2022
GNRT
NON-FINAL ACTION E-MAILED
09/08/2022
CNRT
NON-FINAL ACTION WRITTEN
09/08/2022
DOCK
ASSIGNED TO EXAMINER
09/08/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/03/2021
NWAP
NEW APPLICATION ENTERED
12/03/2021
Continuous trademark protection
Get notified about every new filing that threatens HAEVENCI or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.